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Abstract 
Background: Plasmodium falciparum is transmitted from person to person by Anopheles mosquitoes after complet‑
ing its sexual reproductive cycle within the infected mosquito. An efficacious vaccine holds the potential to interrupt 
development of the parasite in the mosquito leading to control and possibly eradication of malaria. A multi‑compo‑
nent, R0.10C, was developed comprising P. falciparum glutamate‑rich protein (R0) fused in frame to a correctly folded 
fragment of Pfs48/45 (10C). Here, a series of novel adjuvants were screened for their ability to elicit transmission‑
blocking (TB) antibodies.
Methods: The recombinant fusion protein R0.10C was produced in Lactococcus lactis and purified by affinity‑chro‑
matography on a monoclonal antibody (mAb 85RF45.1) against a major epitope for TB antibodies (epitope 1) har‑
boured on R0.10C. Immune‑purified R0.10C was mixed with a series of adjuvants and tested in mice and rats.
Results: In general, all R0.10C formulations elicited high levels of antibodies recognizing native Pfs48/45 in macro‑
gametes/zygotes. TB activity of anti‑R0.10C antisera was assessed in the standard membrane‑feeding assay (SMFA). 
Potency of different adjuvant/R0.10C combinations was tested in mice and rats using aluminium hydroxide (Alum), 
Alum with micellar and emulsion formulations of a synthetic TLR4 agonist, Glucopyranosyl Lipid Adjuvant (GLA), 
stable emulsion (SE)/GLA, AbISCO‑100 and Freund’s adjuvant (as reference). All formulations produced high antibody 
titres recognizing the native Pfs48/45 protein in macrogametes/zygotes. Interestingly, the GLA‑Alum combina‑
tion adjuvant was the most potent inducer of TB antibodies based on serum collected after two immunizations. In 
agreement with previous observations, biological activity in the SMFA correlated well with the level of anti‑Pfs48/45 
antibodies.
Conclusion: The combined data provide a strong basis for entering the next phase of clinical grade R0.10C produc‑
tion and testing.
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Background
Malaria is primarily confined to the poorest tropical areas 
of the world and constitutes one of the world’s greatest 
public health problems [1]. Efforts to eliminate malaria 
transmission through use of insecticides and/or bed nets 
have resulted in only limited success [2]. Vaccines hold 
the potential for effective control and elimination of the 
disease burden. However, despite decades of research 
there is still no clinically applicable vaccine available. 
With the renewed focus on malaria eradication, trans-
mission blocking malaria vaccines (TBMV) which induce 
antibodies that target the sexual stages of the parasite 
have become a focus of malaria vaccine research. One of 
the leading candidates for a TBMV is Pfs48/45, a protein 
expressed in gametocytes and on the surface of gametes 
and zygotes [3–6]. Pfs48/45 is essential for male gamete 
fertility in Plasmodium [7] and anti-Pfs48/45 antibodies 
have been found to prevent zygote development in the 
standard membrane feeding assay (SMFA) [8]. The exact 
mechanism through which these antibodies interfere 
with fertility is unknown but steric hindrance is likely a 
possibility. Irrespective of the mechanism, it has been 
shown in ex vivo assays that there is a strong correlation 
between levels of Pfs48/45-specific antibodies in sera 
from malaria-endemic areas and TB activity in the SMFA 
[9–11].
Pfs48/45 is a relatively cysteine-rich protein with multi-
ple disulfide bonds resulting in antibody epitopes that are 
dependent on tertiary structure rather than linear amino 
acid sequence. A panel of mAbs have been generated and 
characterized with respect to their TB-activity in SMFA 
[12, 13]. Of these, mAb 85RF45.1 exhibits the strongest 
TB activity whereas mAbs 85RF45.2 and 85RF45.3 do 
not exhibit TB activity on their own but may act syner-
gistically with 85RF45.1 [12]. All three mAbs recognize 
conformational epitopes, of which epitope I, defined by 
mAb 85RF45.1, is located in the C-terminal portion of 
Pfs48/45 (10C) [14]. Pfs48/45 and fragments thereof has 
been produced on recombinant form in various expres-
sion systems [5, 6, 15–18]; however, none of these prod-
ucts has reached clinical development phase. Recently, 
correctly folded fragments were produced of Pfs48/45 
(10C) containing all three epitopes and Pfs48/45 (6C) 
containing only TB-epitope 1 fused in frame with the 
N-terminal part of the glutamate rich protein (GLURP) 
in the Lactococcus lactis expression system [19, 20]. This 
system has previously proved efficient for the produc-
tion of GMZ2, an asexual blood-stage vaccine candidate 
[21, 22], and GMZ2 adjuvanted in Al(OH)3 has shown 
good safety and tolerability in phase 1 clinical trials [21, 
23–25].
With the aim of developing a TBMV, the effects of 
different adjuvant formulations were investigated in 
mice and rats on: (1) the production of antigen-specific 
IgG against recombinant and native proteins; and, (2) 
the biological activity of antibodies elicited by vaccina-
tion. The adjuvant vehicles used were either aluminium 
hydroxide (Alum), an oil-in-water stable emulsion (SE) 
or AbISCO®-100, a saponin based adjuvant. Two of these 
formulations (Alum and SE) were supplemented with 
the Toll-like receptor synthetic TLR 4 agonist glucopyra-
nosyl lipid A adjuvant (GLA) [26]. GLA was used in the 
present study because it has been shown to enhance IgG 
responses against the GLURP.R0 component of GMZ2 in 
mice [27], and GLA is safe for use in humans and non-
human primates [28].
Methods
Construction, fermentation and purification of correctly 
folded R0.10C
Construction of the recombinant R0.10C hybrid molecule, 
a fusion protein containing the regions GLURP27–500 and 
Pfs48/45159–428 and a stretch of six histidines in the C-ter-
minus, has been described in detail elsewhere [19]. The 
theoretical molecular weight of the protein is 89.8 kDa of 
which 30.7 kDa originates for the 10C fragment.
All fermentations at the 40L scale were done at the 
cGMP-facility of Gennova, India, using the standard 
proposed medium composition as described earlier [19]. 
Briefly, a fermentor containing reconstituted medium 
with the final pH 7.0, adjusted with sterile 2  N NaOH, 
was inoculated with overnight culture of inoculum. The 
fermenter was programmed to maintain pH 6.5, temper-
ature 30  °C at the low agitation rate (100  rpm) without 
aeration, maintaining anaerobic conditions. At the sta-
tionary phase when no more alkali (2  N NaOH) uptake 
was observed to maintain pH 6.5, the culture was har-
vested from the fermenter. Following clarification of the 
fermentation broth by centrifugation, the culture super-
natant was concentrated five to six times using tangen-
tial flow filtration (TFF) and diafiltered using 2.5  sq  m 
membrane with pore size cut-off of 10 kDa with buffer-1 
(50  mM phosphate buffer, pH 7.0, 6 diafiltration vol-
umes (DV) followed by buffer-2 (50  mM phosphate 
buffer, pH 7.0 and 0.25  M NaCl, 6 DV). The diafiltrate, 
now defined as ‘affinity-input’ containing 10 mM imida-
zole and 5  mM β-ME, was loaded on the Ni2+-Sepha-
rose column pre-equilibrated with 4CV of equilibration 
buffer (50  mM phosphate buffer, pH 7.0, 0.25  M NaCl, 
20 mM Imidazole). After loading affinity-input, the col-
umn was washed with 4 column volumes (CV) of equi-
libration buffer, followed by washing with redox-buffer 
of glutathione exists in both 4  mM reduced (GSH) and 
0.4  mM oxidized (GSSG) states for 60  min. Following 
redox-wash, the recombinant R0.10C was eluted isocrati-
cally with the elution buffer containing 50 mM phosphate 
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buffer, 0.25  M NaCl, 200  mM Imidazole, pH 7.0. The 
peak fraction was finally purified on anti-Pfs48/45 mAb 
45.1 (epitope 1) coupled to agarose using the Amin-
oLink® Plus Immobilization Kit (Pierce: 44894) accord-
ing to the instructions of the manufacturers. The eluate 
contained immune purified R0.10C (correctly folded) 
whereas the run-through contained <1  % of correctly 
folded R0.10C. Eluted samples were concentrated to at 
least 1 mg/ml against 1× phosphate buffered saline (PBS) 
on a Vivaspin20, 30-kDa molecular mass cut-off ultra-
filtration unit (Vivascience, Germany). Protein concen-
trations were measured on a NanoDrop 2000 (Thermo 
Scientific, USA) using a molar extinction coefficient of 
0.3 and Bradford’s method.
Rat and mouse immunogenicity studies
Experimental animals, including female Wistar Hanover 
rats and female CB6F1 (BALB/c ×  C57BL/6 F1 hybrid) 
mice, were selected for the study. The animals were pur-
chased from Charles River and kept in the Laboratory 
Animal Facility Centre of the Radboud University Medi-
cal Centre (RUMC). All procedures regarding animal 
immunization complied with European and national 
regulations.
Immunizations were performed by the subcutaneous 
route three times, 2  weeks apart with 20  µg of R0.10C 
adjuvanted with different formulations in a total volume 
of 100 µl for mice and 200 µl for rats.
Rats receiving adjuvant formulations aluminium 
hydroxide [(Alhydrogel, Brenntag (Alum: SSI (expiry date 
June 2012)], Alum/GLA, SE/GLA and AbISCO-100 and 
for mice complete Freund’s adjuvant (CFA)/incomplete 
Freund’s adjuvant (IFA) (Sigma-Aldrich), Alum/GLA, 
SE/GLA and AbISCO-100 (ISCONOVA). The Freund’s 
group was used for reasons of comparison with the for-
mer MBP-PF10C immunizations previously described [6]. 
For the Alum-based formulation, groups of five animals 
were immunized with R0.10C adsorbed to Alum with or 
without a supplement of 5 µg of an aqueous formulation 
of GLA (IDRI:AQ014). For the SE-based immunization, 
groups of five animals were immunized with R0.10C and 
SE (IDRI:EM030) supplemented with 5 µg of GLA in SE 
(IDRI:EM031). The components of the Alum and SE-
based formulations were mixed gently for 30  min and 
allowed to rest on ice for 1 h before injection. Sera were 
collected from peripheral blood samples on days 0, 14, 28, 
and 42 separated by centrifugation of blood at 1500×g for 
10 min and stored at −20 °C until further analysis.
ELISA
Antibody responses in immunized animals were meas-
ured by ELISA. All experimental steps, except for coat-
ing, were performed at room temperature (RT). Briefly, 
ELISA MaxiSorp microtitre plates (Sterilin® ELISA 
plates, The Netherlands) were coated at 4  °C overnight 
with 50 μl of the R0.10C (2 µg/ml), GLURP.RO (1.4 µg/
ml) or MBP.10C (2 µg/ml) in PBS pH 7.4. Wells were then 
blocked with 5  % skimmed milk powder in PBS for 1  h 
followed by three washings with PBS containing 0.05  % 
Tween-20 (PBST). Plates were incubated with 50 μL two-
fold serial dilutions of sera starting with 1:100 in PBST 
for 4  h at RT. After washing, the plates were incubated 
with 50  μL of 1:3000 diluted rabbit-anti rat IgG-HRP 
(H + L) (DAKO, 1:3,000 diluted in PBST) or rabbit anti-
mouse IgG-HRP (DAKO, 1:4,000 diluted in PBST) for 
2 h. Wells were washed with PBS and subsequently incu-
bated with tetramethyl benzidine (TMB) substrate solu-
tion for 20  min. The colour reaction was stopped with 
0.2  N H2SO4, and the optical density (OD) was read at 
450  nm in an Anthos 2001 Microplate Reader (Labtec 
BV). Midpoint (EC50) values were calculated using 
GraphPad Prism, (GraphPad Software, USA). MBP.10C is 
used for comparison of results with the data as described 
by Outchkourov et al. [6]. The discrepancy between the 
antibody titer measured in the R0.10C and MBP.10C ELI-
SAs is due to antibodies against the R0 region of R0.10C.
Standard membrane feeding assay (SMFA)
Antisera obtained from mice and rats immunized with 
R0.10C were assessed for TB activity by SMFA as pre-
viously described [29, 30]. Briefly, 30 μl of rat or mouse 
serum was mixed with 90 μl of naïve human serum and 
150  μl of in  vitro gametocyte cultures of the P. falcipa-
rum (NF54) and for comparison (NF135.C10 Cambodian 
line [31]) laboratory lines. The mixture was fed to Anoph-
eles stephensi mosquitoes through a membrane feed-
ing apparatus. Pre-immune sera served as the controls. 
Fully engorged mosquitoes were separated and held at 
26  °C. Seven days later, midguts of 20 mosquitoes were 
examined for oocysts. The observed TB activity of serum 
(TRA) was determined as the percentage reduction in 
the arithmetic mean oocyst number in test samples com-
pared to that in controls. The experiment was considered 
valid when at least 85  % of the mosquitoes feeding on 
control sera were infected. Data were analysed by a non-
parametric test by comparing the medians of two groups 
using the Mann–Whitney test, or by comparing three or 
more groups using the Kruskal–Wallis test, followed by 
post-tests. If significance was indicated, Dunn’s analysis 
was used for comparison with the control group.
Results
Purification of properly folded R0.10C
Recently, a correctly folded fragment was produced of 
Pfs48/45 (10C) as a chimera (R0.10C) fused in frame 
with a section of the P. falciparum glutamate rich protein 
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(GLURP.R0) in the Lactococcus lactis expression system 
[19]. R0.10C was immune-purified on mAb 85RF45.1 
bound to agarose beads. The resulting immune-purified 
R0.10C reacted strongly with mAbs against the confor-
mational epitopes 1, 2b and 3 as demonstrated by sand-
wich ELISA (Fig.  1a) suggesting that this preparation 
contains a homogeneous solution of correctly folded 
R0.10C. In contrast, the flow-through (FT) did not show 
an appreciable binding to any of the mAbs (Fig.  1a–c) 
and only affinity-purified R0.10C showed strong reactiv-
ity with mAb 85RF45.1 by Western blotting (Fig. 1c). To 
establish a standard reference curve for estimating the 
percentage of correctly folded protein species in a solu-
tion, immune-purified R0.10C (termed 100  % correctly 
folded) was mixed with the FT containing only misfolded 
antigen to obtain mixtures of 100, 75, 50, 25, 12, 6.5, and 
<1  %, correctly folded R0.10C, respectively. When each 
mixture was tested in the sandwich ELISA, there was a 
strong correlation between the EC50 values and percent-
age of properly folded antigen (Fig. 1d, r = 0.99). Using 
this reference, the Ni-IMAC purification step yields a 
product which contains approximately 5  % correctly 
folded conformers (Fig. 1d).
Immunogenicity of properly folded R0.10C
In order to study the immunogenicity of R0.10C, different 
adjuvants formulations were investigated in both mice 
and rats. Inbred CB6F1 (BALB/c x C57BL/6 F1 hybrid) 
mice were immunized three times at two-week intervals 
with 20  µg of immune-purified R0.10C administered in 
AbISCO, Alum supplemented with GLA, or in an oil-
in-water SE supplemented with GLA. For comparison, a 
control group received R0.10C in Freund’s adjuvant. Sex-
ual blood-stage, specific antibody responses were meas-
ured by ELISA. Two weeks after the last injection (day 
42), all mice had relatively high antibody titres against the 
a
d
e
b c
Fig. 1 R0‑10C purified by mAb45.1‑affinity chromatography. Purification and characterization of correctly folded monomeric R0.10C. a 2‑site ELISA 
with the flow trough (FT) and immune purified antigen (500 ng/well) using mAb 85RF45.1, 85RF45.2b and 85RF45.3 as capture and anti‑HIS‑HRPO 
for detection. b Coomassie blue‑stained 4–12 % Bis–Tris gel of R0.10C purification steps using 5 µg antigen/lane, c Western blot analysis using 
rat mAb 85RF45.1‑HRP for detection. Lane 1, input antigen after Ni2++ column purification; Lane 2, Flow trough (FT: misfolded R0.10C) from the 
mAb Affinity column: lane 3, eluate (immune purified R0.10C (properly folded)) from the mAb affinity column; Lane 4, Markers, the sizes (kDa) of 
the molecular mass markers are indicated. d 2‑site ELISA with the FT, mAb‑Affinity eluted antigen (El) and mixed samples using mAb 85RF45.1 
as capture and mAb 85RF45.2b‑HRPO for detection. e correlation between EC50 titres and percentage of properly folded antigen (R = 0.9944: 
y = 4.59x + 0.505)
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immunogen (Fig. 2a). When assessing the IgG responses 
against the Pfs48/45 components, it was evident that 
R0.10C in SE supplemented with GLA gave the low-
est and significantly different (p  =  0.016) anti-Pfs48/45 
IgG response compared to the control group (Fig.  2b). 
In contrast, R0.10C in Alum supplemented with GLA 
gave a relatively high anti-Pfs48/45 IgG response indis-
tinguishable (p =  0.3) from the response obtained with 
R0.10C in Freund’s adjuvant (Fig. 2b). The finding that an 
Alum-based formulation is as efficient as an oil-in-water 
emulsion was unexpected and warrants further inves-
tigation. A second experiment, including an additional 
group of R0.10C/Alum, was therefore performed in rats. 
Rats were chosen partly to confirm the initial finding 
in a second species and partly because rats can donate 
more blood, allowing analysis of individual samples in 
functional bioassays. Animals were immunized three 
times with 20 µg immune purified R0.10C adjuvanted in 
Alum, Alum/GLA, SE/GLA or AblSCO (Fig.  2c). Com-
pared with the mouse experiment, R0.10C adjuvanted 
in Alum/GLA gave the lowest anti-10C IgG levels and is 
significantly different from the Alum group (p = 0.008). 
Furthermore, R0.10C adjuvanted in Alum gave the high-
est anti-Pfs48/45 IgG response and is also significantly 
different from the SE/GLA group (p < 0.01) but not from 
the AbISCO group (p > 0.2) (Fig. 2d).
Antibodies against GLURP.R0 showed that the lowest 
antibody titers (EC50 titer =  1984 with standard devia-
tion (SD) of 889) was detected for the alum group but is 
only significantly different (p =  0.01) from the SE/GLA 
and AbISCO group. There was no differences in antibody 
titers between the Alum/GLA, SE/GLA and AbISCO 
P = 0.016
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Fig. 2 Immunogenicity of R0.10C. ELISA results of various bleed sera from mice (a b upper graphs) and rats (c, d lower graphs) immunized with 
R0.10C and different adjuvants. 0, 14, 28, and 42 indicate pre‑immune sera, day 14, day 28 and day 42 of the time course of the immunization for 
mouse (a) and rat (c). Mouse sera (a) from day 14 and 28 were not available. The right figures are ELISA results of final bleed (day 42) sera from mice 
(b) and rats (d) immunized with immune purified R0.10C formulated with different adjuvants using 10C as sexual stage antigen (Sex Ag)
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group; EC50 titers 4776 (SD = 2419), 6371 (SD = 4093) 
and 7462 (SD = 4098), respectively.
Inhibition of sexual Plasmodium falciparum fertilization 
by R0.10C antisera
TB activity of anti-R0.10C antisera was assessed in the 
SMFA. The pre-bleed (day 0) of mice and rats did not show 
any TB activity and was used to calculate the per cent 
inhibition of oocyst counts. Two injections of R0.10C for-
mulated in Alum/GLA or AbISCO elicit IgG levels which 
efficiently inhibited (>96 %) oocyst development, whereas 
three injections of R0.10C in SE/GLA and Freund’s were 
required to reach the same level of inhibition (Table  1). 
The same trend was also observed in rats (Table 1).
When testing individual day 42 sera from rats, the TB 
activity of the four adjuvant formulations resulted in 
>99  % inhibition of oocyst development except for one 
rat in the Alum/GLA (TRA 25 %) and one in the AbISCO 
group (TRA 29  %) (Table  2). These two non-blocking 
antisera also gave the lowest anti-Pfs48/45 IgG titres (196 
and 51 respectively).
R0.10C antisera inhibit Plasmodium falciparum growth in a 
strain independent manner
Antigenic variation may limit the breadth of P. falcipa-
rum-inhibiting antibodies. To gauge the breadth of P. 
falciparum inhibition antisera from all animals immu-
nized with R0.10C/Alum was tested for TB activity of 
genetically diverse African and Cambodian P. falciparum 
laboratory lines NF54 and NF135.10C, respectively. The 
individual antisera showed comparable levels of TB activ-
ity (Table 3) for the two strains irrespective of polymor-
phism at amino acid positions 254, 304 and 322 in the 
Pfs48/45 portion of R0.10C, suggesting that anti-R0.10C 
IgG act in a strain-independent manner to control par-
asite fertility in the infected mosquito. Furthermore, 
the TB activity for the alum-immunized rats is higher 
(76–100  %; EC50 titers: 1250–3622) compared with the 
alum/GLA group (0–72 %; EC50 titers: 196–446) tested 
at a dilution of 1/27 for both strains.
Discussion
The development of a TBMV is an attractive goal because 
it holds the potential to accelerate elimination or even 
eradication of P. falciparum malaria. The inclusion of 
a TBMV in these efforts would require a highly immu-
nogenic vaccine formulation with the capacity to induce 
high levels of TB antibodies lasting for at least one trans-
mission season. This is particularly important since 
several malaria antigens have proved to be poorly immu-
nogenic in adjuvants for human use [32, 33]. Recently, a 
new multi-stage vaccine candidate (R0.10C) was devel-
oped consisting of the N-terminal domain of GLURP 
(R0) fused in frame to a functional domain of Pfs48/45 
(10C) [19]. The potential importance of increasing the 
overall immunogenicity of R0.10C and the Pfs48/45 
domain in particular, is suggested by the direct relation-
ship between anti-R0.10C antibody titre and biological 
activity in the SMFA [19]. In the present study, a series of 
adjuvant formulations in small rodents were investigated 
for their ability to enhance antibody responses against 
sexual blood stages. Antisera were also investigated for 
their ability to control parasite fertilization in the SMFA. 
It is evident that both Alum and SE/GLA formulations 
elicited strong TB immunity with five out of five animals 
showing >99 % TRA. In contrast, R0.10C formulated in 
Alum/GLA or in AbISCO was slightly less efficient with 
four out of five animals seroconverting to functional 
antibody titres. All mice and rat sera were tested at a 1/9 
dilution. Testing rat sera from the Alum and Alum/GLA 
group at dilution of 1/27 still resulted in strong TB activ-
ity for the Alum group but not for the Alum/GLA group, 
showing that Alum alone is a better adjuvant for func-
tional antibodies.
Table 1 Infectivity of  P. falciparum Gametocytes to  A. stephensi Mosquitoes in  the presence of  different pooled bleed 
sera from mice and rats immunized with R0.10C formulated with different adjuvants in the Standard Membrane-Feeding 
Assay (SMFA)
Pooled Sera (1:9 diluted) from the different bleeds (Day 0, 14, 28 and 42) were tested in the SMFA. Seven days after membrane feed, the number of infected 
mosquitoes and oocyst density were determined. Inf: total infected mosquitoes from the 20 dissected mosquitoes; TRA, %: percentage of Transmission Reducing 
Activity using the pre-bleed (Day 0) sample for calculation
Day Mice Rats
Freunds Alum/GLA SE/GLA AbISCO Alum Alum/GLA SE/GLA AbISCO
Inf TRA, % Inf TRA, % Inf TRA, % Inf TRA, % Inf TRA, % Inf TRA, % Inf TRA, % Inf TRA, %
0 18 18 19 18 16 17 19 16
14 17 0 11 35 11 26 18 0 20 11 17 2 20 0 17 0
28 7 76 1 97 10 59 4 96 5 94 3 97 10 85 6 91
42 0 100 2 95 1 99 1 99 1 98 1 99 1 99 1 99
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The analysis of specific antibody responses against the 
10C domains of R0.10C suggests that the Alum formula-
tion lead to the highest levels of 10C-specific antibodies 
compared to all other formulations (Fig.  2d). In con-
trast, an oil-in-water emulsion formulation of GLA led 
to relatively lower levels of 10C-specific IgG in mice, but 
not in rats (Fig. 2b). The discrepancy between the anti-
body titer measured in the R0.10C and MBP.10C ELI-
SAs is due to antibodies against the R0 region of R0.10C. 
Since recombinant MBP.10C only share the Pfs48/45-
10C region with the R0.10C fusion protein, MBP.10C 
was used for the detection of 10C-specific antibodies. 
MBP.10C was included in the present study to allow 
comparison with previously published data [6]. Re-test-
ing in a larger group of animals and/or using the 10C 
part alone may help to clarify whether there is indeed a 
specific difference.
The identification and characterization of TB epitopes 
of Pfs48/45 have been facilitated by the availability 
of mAbs with TB activity [8, 12, 13]. In the process of 
developing a Pfs48/45-based TBMV, a series of mAbs 
was used against conformation-dependent epitopes for 
the characterization of recombinant Pfs48/45 [6, 13]. 
Here, it has demonstrated that a R0.10C antigen prepa-
ration which is correctly folded with respect to epitope 
1 of Pfs48/45 elicits high levels of antibodies against 
this epitope in rats with the capacity to inhibit para-
site growth in the mosquito when adjuvanted in Alum, 
Alum/GLA, SE/GLA, or AbISCO. Sera which inhibit a 
high level of TB activity (TRA) also has a low mosquito 
infection rate (Tables  1, 2, 3). Adjuvanted with Alum 
resulted in the highest TB activity (Table  3). Recently, 
Singh and others [20] show that R0.6C (only epitope 1 
Table 2 Infectivity of  P. falciparum Gametocytes to  A. 
stephensi Mosquitoes in  the presence of  day 42 serum 
from rat immunized with R0.10C formulated with different 
adjuvant formulation in the Standard Membrane Feeding 
Assay (SMFA
Sera (1:9 diluted) were tested in the SMFA. Seven days after membrane feed, 
the number of infected mosquitoes and oocyst density were determined. Sera: 
Rat serum from R0.10C-immunized group; Control: feeder with pre-bleed serum 
(day 0) of the group; no. Inf: total infected from 20 dissected mosquitoes; TRA, %: 
percentage of Transmission Reducing Activity; P-value: sample of the control 
(day 0) was used for calculation
NS not significant; SD standard deviation
Group Rat Inf Mean (SD) % P value
Alum 1 1 0.05 (0.22) 99 <0.001
2 0 0.0 (0.0) 100 <0.001
3 0 0.0 (0.0) 100 <0.001
4 1 0.05 (0.22) 99 <0.001
5 0 0.0 (0.0) 100 <0.001
Alum/GLA 6 0 0.0 (0.0) 100 <0.001
7 1 0.05 (0.22) 99 <0.001
8 18 7.85 (4.64) 25 NS
9 1 0.05 (0.22) 99 <0.001
10 1 0.05 (0.22) 99 <0.001
Pre sera 37/40 10.48 (6.12)
SE/GLA 11 2 0.10 (0.31) 99 <0.001
12 2 0.10 (0.31) 99 <0.001
13 1 0.05 (0.22) 99 <0.001
14 1 0.05 (0.22) 99 <0.001
15 0 0.0 (0.0) 100 <0.001
AbISCO 16 0 0.0 (0.0) 100 <0.001
17 16 7.45 (6.39) 29 NS
18 0 0.0 (0.0) 100 <0.001
19 1 0.05 (0.22) 99 <0.001
20 2 0.10 (0.31) 99 <0.001
Table 3 Comparison of  percentage Transmission-Reducing Activity using 2 Pf strains of  different geographical origin 
and sera from rats immunized with R0.10C Alum and Alum/GLA formulation
Day 42 sera (1:27 diluted) were tested in the SMFA. Seven days after membrane feed, the number of infected mosquitoes and oocyst density were determined. Sera: 
rat serum from R0.10C-immunized group; Control: feeder with pooled pre-bleed serum (day 0) of the group. Inf: total infected from 20 dissected mosquitoes; SD: 
Standard deviation; TRA, %: percentage of Transmission Reducing Activity. NF54: African strain and NF153: Cambodian strain
Group Rat NF54 NF135
Inf Mean (SD) TRA, % Inf Mean (SD) TRA, 
%
Alum 1 16 7.35 (6.23) 82 17 6.60 (5.99) 76
2 17 4.45 (4.00) 89 6 0.60 (1.14) 98
3 1 0.05 (0.22) 100 0 0.0 (0.0) 100
4 16 4.30 (4.71) 89 10 0.90 (1.21) 97
5 17 3.20 (2.86) 92 4 0.39 (0.78) 99
Alum/GLA 6 18 27.7 (14.7) 31 17 7.70 (6.87) 72
7 19 38.8 (23.3) 3 20 15.4 (9.2) 45
8 20 41.7 (25.9) 0 18 27.1 (15.2) 3
9 20 17.8 (8.1) 55 18 10.0 (5.85) 64
Pre sera 35/35 39.9 (23.6) 0 40/40 27.8 (12.6) 0
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of Pfs48/45) did also give high TB activity. Further stud-
ies must be performed combining R0.10C and R0.6C for 
immunogenicity data.
The adjuvants tested here (Alum and SE with/with-
out addition of GLA or AbISCO) are all applicable for 
human use [28, 34]. Aluminium salts are the most com-
monly used adjuvants in clinical trials and they have the 
reputation of being safe and give high antibody titres and 
long-lasting antibody responses [34]. Whether R0.10C/
Alum is also a strong immunogen for induction of func-
tional antibodies in humans remains to be determined.
In summary, the Lactococcus lactis expression platform 
was used for production of correctly folded Pfs48/45. 
Since Alum has been used in past malaria vaccine trials 
of GLURP-based vaccine candidates [21, 35], a further 
vaccination study with the R0.10C antigen in combina-
tion with Alum alone can be pursued.
Conclusions
An investigation of immune responses to R0.10C using 
different adjuvants resulted in good antibody response 
with TB activity. A clinical trial with the R0.10C antigen 
in combination with Alum appears to be a favourable 
option.
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